Bernadette Connaughton Sells 2,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Bernadette Connaughton also recently made the following trade(s):

• On Monday, December 1st, Bernadette Connaughton sold 829 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.60, for a total value of $59,356.40.
• On Monday, November 10th, Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $68.48, for a total transaction of $136,960.00.

Halozyme Therapeutics Trading Up 2.7%

Shares of Halozyme Therapeutics stock opened at $75.11 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The company has a market capitalization of $8.83 billion, a price-to-earnings ratio of 15.81, a PEG ratio of 0.32 and a beta of 0.94. The firm’s 50-day moving average price is $67.98 and its two-hundred day moving average price is $66.42. Halozyme Therapeutics, Inc. has a 12-month low of $47.50 and a 12-month high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $1.72 EPS for the quarter, beating the consensus estimate of $1.63 by $0.09. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The business had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. During the same period in the previous year, the business earned $1.27 earnings per share. The company’s revenue was up 22.1% on a year-over-year basis. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HALO has been the topic of several research reports. Citizens Jmp lifted their price target on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the company a “market outperform” rating in a report on Tuesday, November 4th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 14th. Zacks Research downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, December 29th. Finally, Morgan Stanley reduced their price objective on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a research report on Monday, October 20th. Seven analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Hold” and a consensus price target of $75.10.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its stake in Halozyme Therapeutics by 2,136.0% in the 3rd quarter. CWM LLC now owns 23,881 shares of the biopharmaceutical company’s stock valued at $1,751,000 after purchasing an additional 22,813 shares during the period. Arbor Investment Advisors LLC purchased a new position in shares of Halozyme Therapeutics in the third quarter worth about $1,316,000. Monument Capital Management purchased a new position in Halozyme Therapeutics in the 3rd quarter valued at approximately $2,015,000. Redhawk Wealth Advisors Inc. grew its position in shares of Halozyme Therapeutics by 14.8% in the second quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock valued at $1,947,000 after purchasing an additional 4,827 shares in the last quarter. Finally, Pacer Advisors Inc. grew its holdings in Halozyme Therapeutics by 2,054.7% during the 3rd quarter. Pacer Advisors Inc. now owns 478,874 shares of the biopharmaceutical company’s stock valued at $35,121,000 after buying an additional 456,649 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.